Galveston, TX – According to filings with the U.S. Securities and Exchange Commission, Noninvasix is raising $3,889,109.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Graham Randall played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Noninvasix

Noninvasix is developing non-invasive precision oximetry, which will allow doctors for the first time to accurately monitor oxygen sufficiency within organs without invasive catheters. Inadequate organ oxygenation is a major cause of death and permanent disability in hospitals. Pulse oximetry only measures systemic arterial oxygenation. Prompt recognition of low venous oxygenation can be used to guide therapeutic interventions and reduce adverse outcomes.

To learn more about Noninvasix, visit http://www.noninvasix.com/

Contact:
Graham Randall, President and Chief Executive Officer
409-772-2965
grandall@noninvasix.com
https://www.linkedin.com/in/grandall/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved